Speakers
The 2021 List of Faculty below will be regularly updated
Thierry Auperin
Thierry Auperin, PhD, is Vice President, Medical Communications and Training, Alnylam Pharmaceuticals, Cambridge MA. He joined Alnylam Pharmaceuticals in 2019 as Vice President, Medical Communications and Training
Jennifer Bock
Jennifer Bock, Partner, McDermott Will & Emery, focuses her practice on representing public, private and emerging companies and investors in domestic and cross-border mergers and acquisitions, finance, joint ventures, private equity investments and other business transactions. Jennifer has advised companies on corporate issues in a wide range of industries, including the consumer goods, technology, health/life sciences, industrial and energy industries.
Pravin Chaturvedi
Pravin Chaturvedi, PhD, is CEO of OCEANYX Pharmaceuticals and Chair of the Scientific Advisory Board for NAPO Pharmaceuticals, Woburn MA, USA. Dr Chaturvedi is the Summit Honorary Chair. He is widely recognized one of MA’s key opinion leaders in Biotechnology. He has developed over 7 new treatments in CNS, GI and viral diseases over his career.
James Cornwall
James Cornwall has close to 30 years professional experience in the pharmaceutical and CRO industries, working across a range of disciplines including academic research, clinical development, corporate development and investing. He works with the investment team in the London, Boston and Menlo Park offices to source and evaluate new clinical co-development (CCD) investment opportunities and supports existing CCD investments.
Rebecca Dufur
Rebecca (Becky) Dufur, Associate, McDermott Will & Emery, focuses her practice on the representation of leading academic and research institutions, pharmaceutical, biotechnology and medical device companies in complex licensing, collaboration and strategic alliance transactions.
Vanessa Elharrar
Vanessa Elharrar, M.D., MPH, is Vice President Vaccines Strategy Lead within PPD Biotech. She has been focused exclusively on COVID-19 clinical development since the beginning of the pandemic. She has 14+ years experience in infectious disease clinical research and NIH leadership.
Eric Evans
Executive Committee, Mass Medical Angels, Boston MA. Life Sciences Entrepreneur and Investor. Eric has been an executive and consultant in the life sciences for over thirty years, holding leadership roles in biotech, medical device and diagnostic companies.
Marc de Garidel
Chief Executive Officer and Member of the Board of Directors, AZTherapies, Inc. Prior to joining AZTherapies, Mr. de Garidel served as CEO of Corvidia Therapeutics, a private Boston-based cardiorenal-focused clinical-stage company that was acquired by Novo Nordisk in July 2020 for $2.1 billion. Mr. de Garidel continues to serve as Chairman of the Ipsen Board of Directors.
Naji Gehchan
Naji Gehchan, MD, is Global Development Leader Oncology at Eli Lilly leading the development of an oncology asset from early to late phase. Prior to this role, he led Northeast USA sales teams in diabetes bringing life-changing medicines to Healthcare Providers helping patients with diabetes.
Shahin Gharakhanian
Shahin Gharakhanian, MD, DPH, specializes in Drug & Vaccine Clinical Development & Medical Affairs, based in the Cambridge Innovation Center. He has extensive track record in Pharmaceutical Medicine, Executive Leadership & Management. Dr Gharakhanian has led or managed projects for 12 different companies, ten brands in different geographies (Asia, Europe, USA) including four NDA/MAA/launches, most recently a 2011 “blockbuster” in the US.
Frederic Jallat
Dr. Frédéric Jallat is currently Professor, Academic Director of the Advanced Master in Biopharmaceutical Management (MsM – Paris & London), Associate Research Fellow at ESCP Business School, and an affiliated Professor at Sciences Po. Paris. He is currently working, as Co-Academic Director of the Advanced Management Program in Life Sciences and Health (APiL), on the development of a major initiative for entrepreneurship and innovation together with Institut Pasteur.
Sophie Kornowski
Dr. Sophie Kornowski joined Gurnet Point Capital in 2018 from Roche, a leading healthcare company based in Switzerland, where she was Executive Vice-President, global Head of Partnering. In this role, Dr. Kornowski developed and maintained over 200 external partnerships with research institutions, Biotech, Pharma and Healthcare Information Technology companies worldwide.
Cécile Le Camus
Cecile Le Camus, MD, Former head of the US Medical Affairs at Vertex Pharmaceuticals, where she has with her team supported a number of successful launches, striving to generate and communicate insights, evidence, and education that enable healthcare providers, payers, and policymakers to make informed decisions for better patient outcomes.
Retsina Meyer
Retsina Meyer, PhD, Head of strategic projects and Alliances at Delix Therapeutics. Boad of Advisors, Museum of Science, Boston, MA.
Tibor Nemes
Tibor Nemes is President of Stallergenes Greer, Americas, since 2018. Stallergenes Greer has more than one hundred years of combined expertise in allergy and allergen immunotherapy (AIT), and has offices in 19 countries with a commercial distribution network in 40 countries. In 2016 Tibor was serving as Global Head of Technical Operations. He achieved profitability in 2019 for the Americas region in parallel to helping take the company private.
Rodger Novak
Dr. Rodger Novak, President and Chairman of CRISPR Therapeutics, he co-founded the company together with Emmanuelle Charpentier and Shaun Foy in November 2013, and has served as a Director on the Board of Directors since inception. Rodger is an experienced biotechnology and pharmaceutical executive, and former Professor of Microbiology at the Vienna Biocenter in Austria.
Nawal Ouzren
Nawal Ouzren, Chief Executive Officer, SENSORION since April 2017. She has around 20 years of experience in operational and strategic management within the pharmaceutical and biotech industry. Mrs. Ouzren started out at GE before moving to Baxter, where she was Strategy and Operational Excellence Manager, Quality Operations Director and Senior Director Strategy before becoming Vice President of the BioSimilars business unit.
Kamilla Rolsted
Kamilla Rolsted, PhD, MBA, Sr. Exec. Consultant, UCPH & Sector Specialist, Translution Capital. She is a life science executive with 20+ years of industry experience. Currently, she is Sr. Exec. Consultant at The Faculty of Health and Medical Sciences/UCPH focusing on innovation and entrepreneurship. She is also advising Nordic listed and non-listed biotech companies in equity-based fund raisings as part of Translution Capital, and finally, she is the co-founder of Isanans Pharma, a biotech company focusing on ophthalmology.
Lou Shipley
Lou Shipley serves as an executive-in-residence at General Catalyst, sits on the Board of Directors of Wasabi, CustomerGauge, SentryOne, Fairmarkit and Teamworks, and is a lecturer at MIT Sloan School of Management and the Harvard Business School, where he instructs, mentors, coaches the next generation of entrepreneurs. A multi time successful tech CEO. An inspiring teacher. A sought after board member. A trusted mentor. A popular tech-market commentator, writer and speaker.
Mark Stencik
Mark Stencik, Executive Director, Business Development & Licensing, Merck Boston Innovation Hub. Mark has nearly twenty years of Biotech/Pharma experience in business development and licensing and raising capital.
Kenneth Turner
Kenneth Turner is President and CEO of the Massachusetts Life Sciences Center (MLSC), an economic development and investment agency dedicated to supporting the growth and development of the life sciences in Massachusetts. He directs and oversees the center’s operations, investment strategy, programs, and partnerships.
